35986841_10216840653711318_1105697261150535680_n
Normal view MARC view ISBD view

Assessment of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients : Incidence, Risk Factors, and Prevention RS502 RSPL2.1 // GP // Prof. Dr. Soheir Aboelazm Diab // T.A. Mennat Allah Hassan Kamal (2018 - 2019)

By: Lojaine Hesham Fawzy 150249.
Contributor(s): Nada Akmal El kilany 150667 | Shrouk Hassan Mahdy 155411 | Ibrahim Mohamed Negm 155409.
Material type: TextTextSeries: PHARMACY DISTINGUISHED PROJECTS 2019. Publisher: Giza : MSA, 2019Description: 50 p.Subject(s): Breast cancer -- CardiotoxicityDDC classification: 615.704 Online resources: FULL TEXT PRESS HERE Summary: Background: Anthracycline-based chemotherapy has played a significant role in the treatment of various breast cancer stages with reduced rates of both relapse and mortality. However their benefits have been limited due to their adverse events ranging from myelosuppression to well-established risk of cardiotoxicity. Aim: Investigate the correlation between incidence of cardiotoxicity and risk factors in breast cancer patients treated with Anthracyclines and outline current strategies for prevention of Anthracycline induced cardiotoxicity. Subjects and Method: 60 breast cancer patients, (stages II&IIIA), with age ranging from 30 to 65 years, newly diagnosed and scheduled for chemotherapy .Our study population were classified into group 1 (30 patients receiving Anthracycline-based chemotherapy) and group 2( 30 patients receiving Trastuzumab combined with anthracycline-based chemotherapy). Parameters to be measured: ejection fraction, blood pressure, body mass index, and baseline heart rate to record any case of Heart Failure (HF) following anthracyclines treatment. Results: The main comorbidities related to cardiotoxicity among study population were hypertension (44%), diabetes (31%), obesity (90%), and age above 55 years (48%). Baseline ejection fraction recorded for all patients ranges from (42% to 76%). (26 patients) had already diastolic dysfunction grade 1, but only (4 patients) had a substandard ejection fraction. (13 patients) had changes in chemotherapy regimen based on ejection fraction. Group (1) was associated with a HF incidence rate (6.7%) compared to group (2) having significantly increased HF incidence rate (20%). Conclusions: Group (2) had a significant increased incidence of cardiotoxicity. Our study,among previous studies, shed a light about routine echocardiography prior to anthracycline therapy and might eventually lead to current practice guidelines modifications. Keywords: Anthracycline, cardiotoxicity, incidence, Trastuzumab, Echocardiography, prevention.
List(s) this item appears in: Pharmacy D. G. P 2018 / 2019
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Distinguished Graduation Projects Distinguished Graduation Projects Centeral Library
Soft Copy located on library Cataloge
GP37PH2019Clinical Pharmacy (Browse shelf) Available 82194

Pharmacy - Clinical Pharmacy

Background: Anthracycline-based chemotherapy has played a significant role in the
treatment of various breast cancer stages with reduced rates of both relapse and mortality.
However their benefits have been limited due to their adverse events ranging from
myelosuppression to well-established risk of cardiotoxicity.
Aim: Investigate the correlation between incidence of cardiotoxicity and risk factors in breast
cancer patients treated with Anthracyclines and outline current strategies for prevention of
Anthracycline induced cardiotoxicity.
Subjects and Method: 60 breast cancer patients, (stages II&IIIA), with age ranging from 30
to 65 years, newly diagnosed and scheduled for chemotherapy .Our study population were
classified into group 1 (30 patients receiving Anthracycline-based chemotherapy) and group 2(
30 patients receiving Trastuzumab combined with anthracycline-based chemotherapy).
Parameters to be measured: ejection fraction, blood pressure, body mass index, and baseline
heart rate to record any case of Heart Failure (HF) following anthracyclines treatment.
Results: The main comorbidities related to cardiotoxicity among study population were
hypertension (44%), diabetes (31%), obesity (90%), and age above 55 years (48%). Baseline
ejection fraction recorded for all patients ranges from (42% to 76%). (26 patients) had already
diastolic dysfunction grade 1, but only (4 patients) had a substandard ejection fraction. (13
patients) had changes in chemotherapy regimen based on ejection fraction. Group (1) was
associated with a HF incidence rate (6.7%) compared to group (2) having significantly increased
HF incidence rate (20%).
Conclusions: Group (2) had a significant increased incidence of cardiotoxicity. Our
study,among previous studies, shed a light about routine echocardiography prior to anthracycline
therapy and might eventually lead to current practice guidelines modifications.
Keywords: Anthracycline, cardiotoxicity, incidence, Trastuzumab, Echocardiography,
prevention.

There are no comments for this item.

Log in to your account to post a comment.

Click on an image to view it in the image viewer